Jahangeer Basha

Jahangeer Basha

Auto-generated profile, based on publicly available information

Jahangeer Basha

Department of Gastroenterology, AIG Hospitals, Hyderabad, India

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2022 in Endoscopy
Verified
Journal Article
Closed access
PDF file
RCRadhika Chavan
Radhika Chavan
ZNZaheer Nabi
Zaheer Nabi
Sundeep LakhtakiaSundeep Lakhtakia
Sundeep Lakhtakia
RGRajesh Gupta
Rajesh Gupta
BJBasha Jahangeer
Basha Jahangeer
NRNageshwar D. Reddy
Nageshwar D. Reddy
Background Disconnected pancreatic duct (DPD) after development of walled-off necrosis (WON) predisposes to recurrent (peri)pancreatic fluid collection (PFC). In this randomized controlled trial, we compared plastic stents with no plastic stent after removal of a large-caliber metal stent (LCMS) on incidence of recurrent PFCs in DPD. Methods Consecutive patients with WON who underwent endoscopic ultrasound (EUS)-guided drainage with LCMS between September 2017 and March 2020 were screened for eligibility. At LCMS removal (4 weeks after drainage), patients with DPD were randomized to plastic stent or no stent groups. The primary outcome was incidence of recurrent PFC at 3 months. Secondary outcomes were technical success of plastic stent deployment, adverse events, stent migration, and recurrence of PFC at 6 and 12 months. Results 236 patients with WON underwent EUS-guided drainage using LCMS, and 104 (males 94, median age 34 years (interquartile range [IQR] 26–44.7) with DPD were randomized into stenting (n = 52) and no-stenting (n = 52) groups. Plastic stent deployment was successful in 88.5 %. Migration occurred in 19.2 % at median follow-up of 8 months (IQR 2.5–12). Recurrent PFCs occurred in six patients at 3 months (stent n = 3, no stent n = 3). There was no significant difference in PFC recurrence between the two groups at 3, 6, and 12 months. Reintervention was required in seven patients with recurrent PFCs, with no significant difference between the two groups. Conclusion In patients with WON and DPD, deployment of plastic stents after LCMS removal did not reduce recurrence of PFC.

18 August 2020 in Gut
Verified
Journal Article
Open access
PDF file
JBJahangeer Basha
Jahangeer Basha
SLSundeep Lakhtakia
Sundeep Lakhtakia
ZNZaheer Nabi
Zaheer Nabi
PPPartha Pal
Partha Pal
RCRadhika Chavan
Radhika Chavan
NDNageshwar Reddy Duvvur
Nageshwar Reddy Duvvur
Disconnected pancreatic duct (DPD) is a frequent occurrence in cases with walled-off necrosis (WON). The impact of DPD on recurrence of collection after removal of metal stents is not clear. Also, association between DPD and new-onset diabetes mellitus (DM) is not well known. In a large cohort of patients with WON, we observed DPD in majority (3/4th) of the cases. The presence of DPD was a significant risk factor for the recurrence of fluid collections as well as new-onset DM. However, the incidence of recurrent fluid collections and the requirement of reintervention was low (<10%).

24 September 2025 in Gut
Verified
Journal Article
Open access
PDF file
JBJi Young Bang
Ji Young Bang
RPRajesh Puri
Rajesh Puri
Sundeep LakhtakiaSundeep Lakhtakia
Sundeep Lakhtakia
STShyam Thakkar
Shyam Thakkar
IWIrving Waxman
Irving Waxman
SVShyam Varadarajulu
Shyam Varadarajulu
Background Although surgical gastrojejunostomy (SGJ) is the standard method for palliation of gastric outlet obstruction (GOO), an endoscopic method—endoscopic ultrasound-guided gastroenterostomy (EUS-GE)—has been proposed as a novel, less invasive approach. Objective We compared both methods to determine whether clinical outcomes for EUS-GE are superior to surgery. Design We conducted a multicentre, randomised superiority trial of patients with malignant GOO to receive either EUS-GE or SGJ. Primary endpoint was composite measure, consisting of Gastric Outlet Obstruction Scoring System (GOOSS) score of 0 or 1 at hospital discharge, need for reinterventions or supplemental nutrition, or procedure-related adverse events during 6-month follow-up or until death. Secondary endpoints were time to solid diet, length of hospitalisation, health-related quality of life (HRQoL) and treatment costs. Results 74 patients were randomly assigned to EUS-GE (38 patients) or SGJ (36 patients). Primary endpoint occurred in 7.9% of patients who received EUS-GE and 38.9% in SGJ (risk difference −31.0%, 95% CI −47.6% to −11.4%, p=0.002). EUS-GE was associated with more rapid advancement to solid diet (median 2 days (P25–P75, 2–3) vs 5 days (P25–P75, 3.5–9)), shorter hospitalisation (median 3 days (P25–P75, 3–6) vs 9 days (P25–P75, 6–12.5)), better HRQoL for physical (p=0.0016) and social functioning (p=0.011) and lower treatment costs (US$33 934 vs US$51 437, difference −US$17 503 (95% CI −US$27 807 to −US$7920)). Conclusion In this randomised trial, EUS-GE was superior to SGJ with regards to oral intake, need for reinterventions or supplemental nutrition, length of hospitalisation, quality of life and treatment costs. Trial registration number NCT05548114.

10 February 2022 in Gut
Verified
Journal Article
Closed access
PDF file
NJNitin Jagtap
Nitin Jagtap
JKJ Kiran Kumar
J Kiran Kumar
RCRadhika Chavan
Radhika Chavan
JBJahangeer Basha
Jahangeer Basha
MTManu Tandan
Manu Tandan
DRD Nageshwar Reddy
D Nageshwar Reddy
Objective In patients with an intermediate likelihood of choledocholithiasis, European Society of Gastrointestinal Endoscopy (ESGE) guidelines recommend endoscopic ultrasound (EUS) or magnetic resonance cholangiopancreatography (MRCP) to diagnose choledocholithiasis to make the indication for endoscopic retrograde cholangiopancreatography (ERCP) treatment; there is no randomised control trial to compare both in this setting. Design Patients with suspected choledocholithiasis satisfying ESGE guideline’s intermediate likelihood were screened for this single-centre randomised controlled trial between November 2019 and May 2020. The enrolled patients were randomised to either EUS or MRCP. ERCP was performed in stone positive cases or if clinical suspicion persisted during follow-up. Negative cases underwent a further 6-month clinical follow-up. Main outcome was accuracy (sensitivity/specificity) of both tests to diagnose choledocholithiasis, with ERCP or follow-up as a gold standard. Results Of 266 patients, 224 patients (mean age: 46.77±14.57 years; 50.9 % female) were enrolled; overall prevalence of choledocholithiasis was 49.6%, with a higher frequency in the MRCP group (63/112 vs 46/112 for EUS). Both sensitivity of EUS and MRCP were similarly high (92%–98%), without significant differences between the two groups. The negative predictive value and likelihood ratio + were significantly higher in EUS arm (p<0.05). The percentage of ERCPs either incorrectly halted back (false negatives: EUS: 2 vs MRCP: 5) or performed unnecessarily (false positives: EUS: 1 vs MRCP: 2) was low in both groups. Conclusion The performance parameters of both EUS and MRCP are comparable for detecting choledocholithiasis in the intermediate-risk group of choledocholithiasis and the choice of a test should be based on local expertise, availability of resources and patient preference. Trial registration number NCT04173624.

23 May 2024 in Endoscopy
Verified
Journal Article
Closed access
PDF file
KKKrithi Krishna Koduri
Krithi Krishna Koduri
NJNitin Jagtap
Nitin Jagtap
SLSundeep Lakhtakia
Sundeep Lakhtakia
BJBasha Jahangeer
Basha Jahangeer
SAShujaath Asif
Shujaath Asif
DRD. Nageshwar Reddy
D. Nageshwar Reddy
Background Endoscopic ultrasound (EUS)-guided drainage of walled-off necrosis (WON) using either plastic or metal stents is the mainstay of WON management. Our single-center randomized controlled trial aimed to evaluate the efficacy of biflanged metal stents (BFMSs) and plastic stents for WON drainage. Methods Patients with symptomatic WON amenable to EUS-guided drainage were randomized to receive either BFMSs or plastic stents. The primary outcome was reintervention-free clinical success at 4 weeks. Secondary outcomes were: overall clinical success (complete resolution of symptoms and significant reduction in size of WON [<50% of original size and <5 cm in largest diameter at 4-week follow-up]); number of reinterventions; adverse events (AEs); hospital stay for first admission; and medium-term outcomes at 6 months (recurrence, disconnected pancreatic duct, chronic pancreatitis, and new-onset diabetes mellitus). Results 92 patients were randomized: 46 in each arm. The reintervention-free clinical success rate was significantly higher in the BFMS group on intention-to-treat analysis (67.4% vs. 43.5%; P = 0.02). Overall clinical success at 1 month was similar in both groups. There were significantly fewer reinterventions (median 0 [IQR 0–1] vs. 1 [0–2]; P = 0.03) and shorter hospital stays in the BFMS group (7.0 [SD 3.4] vs. 9.1 [5.5] days; P = 0.04). There were no differences in procedure-related AEs, mortality, or medium-term outcomes. Conclusions BFMSs provide better reintervention-free clinical success at 4 weeks, with shorter hospital stay and without increased risks of AEs, compared with plastic stents for EUS-guided drainage of WON. Medium-term outcomes are however similar for both stent types.

24 January 2024 in Endoscopy
Verified
Journal Article
Closed access
PDF file
NGNitish Gurav
Nitish Gurav
NJNitin Jagtap
Nitin Jagtap
VKVinod Koppoju
Vinod Koppoju
KSKiran Sekhramantri
Kiran Sekhramantri
SAShujaath Asif
Shujaath Asif
SKSvss Kiran
Svss Kiran
Background Extracorporeal shockwave lithotripsy (ESWL) and/or endoscopic retrograde cholangiopancreatography (ERCP) are recommended as first-line therapy for painful uncomplicated chronic pancreatitis with obstructed main pancreatic duct (MPD) in the pancreas head/body. However, predictors of pain relief after ESWL are unknown. We evaluated independent predictors of persistent pain in patients who underwent ESWL for chronic pancreatitis. Methods 640 consecutive adult patients with chronic pancreatitis, who underwent successful ESWL with ERCP and pancreatic duct (PD) stent placement, were followed for 12 months. The pain was assessed at baseline and at 12 months using the Izbicki Pain Score, with a score decrease of >50% considered pain relief. Independent predictors of pain relief were derived from logistic regression analysis. Results Of 640 patients (mean age 36.71 [SD 12.19] years; 60.5% men), 436 (68.1%) had pain relief and 204 (31.9%) had persistent pain. On univariate analysis, older age, male sex, alcohol and tobacco intake, longer duration of symptoms, dilated MPD and MPD stricture were associated with persistent pain at 12 months (P<0.05). Consumption of alcohol (odds ratio [OR] 1.93, 95%CI 1.26–2.97), tobacco (OR 4.09, 95%CI 2.43–6.90), duration of symptoms (OR 1.02, 95%CI 1.01–1.04), MPD size (OR 1.22, 95%CI 1.11–1.33), and MPD stricture (OR 8.50, 95%CI 5.01–14.42) were independent predictors of persistent pain. Conclusions Alcohol, tobacco, duration of symptoms, MPD size and stricture were independent predictors of persistent pain after successful ESWL. A multidisciplinary team approach that includes behavioral therapy and surgical options should be considered for such patients.